about
Romiplostim in the management of thrombocytopenia in a patient with autoimmune hepatitis.Circadian variation of cytotoxicity and genotoxicity induced by an immunosuppressive agent "Mycophenolate Mofetil" in rats.Cytopenia Occurrence in Kidney Transplant Recipients Within Early Post-transplant Period.Novel immunosuppressive agent caerulomycin A exerts its effect by depleting cellular iron contentHaematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.Exercise capacity following pediatric heart transplantation: A systematic review.Preclinical Safety Assessment of Standardized Extract of Centella asiatica (L.) Urban Leaves.Autoimmune hemolytic anemia in patients with liver transplants for primary biliary cirrhosis: Three case reports and a review of the literature.Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation.Nonsurgical care of intestinal and multivisceral transplant recipients: a review for the intensivist.Current evaluation and management of anemia in patients with inflammatory bowel disease.Ex vivo alloanergization with belatacept: a strategy to selectively modulate alloresponses after transplantation.Management of inflammatory bowel disease-related anemia and iron deficiency with specific reference to the role of intravenous iron in current practice.Thrombocytopenia after liver transplantation: Should we care?Prediction of clinically relevant safety signals of nephrotoxicity through plasma metabolite profiling.Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians
P2860
Q33402513-1ADF8E37-7325-4800-AA96-1196997B1D75Q33434301-A86BF849-B267-42AB-9C95-EA8DEE185870Q33440336-9701E33E-F4B4-46CC-BD4B-0CEF8B3882FBQ35484363-A0C670AE-9B2D-4FAD-B1F7-9480D0F033E7Q35554823-B9774300-8886-491D-9906-66BAD5B6F0E6Q36350067-BFDE489B-5C93-4D8A-9BBC-134124CF4C14Q36485796-09D7F79F-45C7-4EBC-A430-F71FC7DBAB77Q36622173-A177BB05-5872-4168-A8C3-869EC4762F97Q37013588-E6EE245A-D551-4618-BF9E-ECED1EAD598AQ38021735-BF5B8DA4-ED65-4EE5-B848-780479F22707Q39019386-5A0C598D-0A8B-4F9D-991E-F0E2A78A0F10Q43655192-63FED6D7-D57A-4EC9-BECD-F3197385B484Q47821861-99B32C03-97C4-4CFE-94F1-9875C6BB097EQ54239049-1DA3526F-79B9-42AB-9D68-7C81F9299F5DQ55651995-8FCB57EB-1384-49DE-8616-81C32DD880C9Q58805821-C61A3FFB-C703-41FF-86A9-9EA10733822B
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Hematologic toxicity of immunosuppressive treatment.
@ast
Hematologic toxicity of immunosuppressive treatment.
@en
type
label
Hematologic toxicity of immunosuppressive treatment.
@ast
Hematologic toxicity of immunosuppressive treatment.
@en
prefLabel
Hematologic toxicity of immunosuppressive treatment.
@ast
Hematologic toxicity of immunosuppressive treatment.
@en
P1476
Hematologic toxicity of immunosuppressive treatment
@en
P2093
Del Tacca M
P304
P356
10.1016/J.TRANSPROCEED.2004.03.016
P407
P577
2004-04-01T00:00:00Z